ADP014 / Alector - LARVOL DELTA

FEASIBILITY OF DETERMINING DIFFERENCES IN EARLY-STAGE VS. LATE-STAGE COLORECTAL (CRC) CANCER SENSITIVITY OF EMERGING BLOOD-BASED BIOMARKERS FOR CRC SCREENING (DDW 2024) - "3%; ratios of early-stage vs. late-stage CRC of 78: 68:3 or 58:4 (Chung et al 0 3 Imperiale et al 014 Church et al 014); and sensitivities for early-stage vs. late-stage CRC of 6 % and 100% 65% and 93% or 68% and 87% (all aggregating to meet CMS min )... In most scenarios studies of 0 000-80 000 persons would be required in order to have at least 80% power to detect a significant difference between early-stage vs. late-stage CRC sensitivity (Figure). In general larger sample sizes would be required with lower overall CRC prevalence lower relative prevalence of late stage CRC and smaller differences between early-stage and late-stage sensitivities."

Biomarker • Colorectal Cancer • Oncology

Alector Provides 2021 Corporate Portfolio Update (GlobeNewswire) - "AL101 Phase 1a data in healthy volunteers expected in 2021....Alector is evaluating the possibility of a subcutaneous administration of AL101 in neurological diseases, including Parkinson’s disease with specific genetic mutations and Alzheimer’s disease (AD)....INVOKE-2, Phase 2 trial evaluating AL002 in participants with early Alzheimer’s disease has initiated patient screening....Phase 1b study evaluating AL003 in participants with Alzheimer’s disease to report data in 2021: The AL003 clinical development program...has completed enrollment of AD patients in the Phase 1b study...Planning for first-in-human study for ADP014...In the next 18 months, Alector plans to initiate Phase 1 development for its latest prioritized product candidate that targets MS4A4A, a major risk gene for AD..."

Enrollment closed • New P1 trial • P1 data • Trial status • Alzheimer's Disease • CNS Disorders • Parkinson's Disease